Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Breast Neoplasms 23Ovarian Neoplasms 18Neoplasm Metastasis 12Triple Negative Breast Neoplasms 9Prostatic Neoplasms 9Pancreatic Neoplasms 8Neoplasms 8Fallopian Tube Neoplasms 6Squamous Cell Carcinoma of Head and Neck 4Advanced Solid Tumors 4Small Cell Lung Carcinoma 3Recurrence 3Head and Neck Neoplasms 3Endometrial Neoplasms 3Carcinoma, Squamous Cell 3Solid Tumors 2Sarcoma 2Neuroendocrine Tumors 2Lymphoma 2Lung Neoplasms 2Hodgkin Disease 2Fanconi Anemia, Complementation Group D1 2Carcinoma, Non-Small-Cell Lung 2Advanced Solid Tumours 2Advanced Solid Tumor 2Advanced Cancer 2Triple Negative Metastatic Breast Cancer 1Thymoma 1Thrombocytosis 1Solid Tumor 1

Interventions

Paclitaxel 12Gemcitabine 9atezolizumab 8Carboplatin 8Bevacizumab 6tocilizumab 4navitoclax 4liposomal doxorubicin 4Irinotecan 4Erlotinib Hydrochloride 4Cetuximab 4Sunitinib 3Oxaliplatin 3Leucovorin 3Injections 3Fluorouracil 3Docetaxel 3Cyclophosphamide 3tumor necrosis factor-alpha, CNGRC fusion protein, human 2tislelizumab 2temsirolimus 2ridaforolimus 2plocabulin 2pembrolizumab 2pazopanib 2olaparib 2obinutuzumab 2linifanib 2fludarabine 2envafolimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Solid Tumors × olaparib × Clear all
NCT00777582 2026-05-08

Phase I Comparative Bioavailability Study

AstraZeneca

Phase 1 Active not recruiting
197 enrolled
Other solid neoplasm

Solid Tumors

NCT00819221 2022-08-30

AZD2281 in Combination With Liposomal Doxorubicin in Advanced Solid Tumours

AstraZeneca

Phase 1 Terminated
44 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡